Health & Fitness
Health and Fitness
Health and Fitness
Fri, February 27, 2009
Thu, February 26, 2009 Candela Donates Its Gold Standard Vbeam Pulsed Dye Laser to Vietnam Clinic
WAYLAND, Mass.--([ BUSINESS WIRE ])--Candela Corporation (NASDAQ:CLZR),pioneers of the safest and most effective vascular laser technology in the world, announced today that it has donated its Vbeam® pulsed dye laser to support the opening of the Vietnam Vascular Anomalies Unit at Nguyen Tri Phuong Hospital in Vietnam. The donation was in a partnership with the University of Medicine and Pharmacy of Ho Chi Minh City, Baylor College of Medicine, Harvard Medical School, Massachusetts General Hospital and Beckman Laser Institute. This is the first multidisciplinary clinic in the country to offer free laser treatments to infants and children with many different vascular lesions such as hemangiomas, port wine stains, venous malformations, arteriovenous malformations and lymphatic malformations.
The lead doctors in the clinic who will be offering the laser treatments include: (in Vietnam) Dr. Minh Hoang, Chief of Dermatology, Nguyen Triphuong Hospital, Ho Chi Minh City; (US collaborators) Dr. Martin Mihm (MGH/Harvard), Dr. Thuy Phung, (Baylor), Dr. Thanh Nga Tran (MGH/Harvard), and Dr. J. Stuart Nelson (Beckman Laser Institute). These physicians will help lecture and train the clinic staff every three to six months.
At an opening ceremony last week, Dr. Stuart Nelson trained and demonstrated the Vbeam laser procedures on approximately 20 – 30 patients with many different anomalies including port wine stains, and red and brown lesions.
"The formation of the clinic is the culmination of many years of hard work and persistence by Dr. James Hsia, Chief Technical Officer of Candela Corporation and Dr. Rox Anderson, Director of the Wellman Laboratories at MGH, who had the vision and insight to put this initiative together," said Candela CEO and President Gerard E. Puorro. "We are very pleased to help lead the effort with the donation of our Vbeam Perfecta laser and offer the children of Ho Chi Minh City an opportunity to have their vascular malformations treated safely and effectively. In addition, we thank the physician members who will be running the clinic, and diagnosing and performing the treatments."
About CANDELA: Candela Corporation manufactures and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, Candela markets and services its products in 86 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 20 years ago, and currently has an installed base of over 13,500 systems worldwide. Visit Candela on the Web at [ http://www.candelalaser.com ].
Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela Corporation's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. These statements include declarations regarding our or our management's beliefs and current expectations. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of such terms or other comparable terminology. These forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. The risks and uncertainties that may affect forward-looking statements include, among others: the availability of, and our ability to successfully implement strategic and operational alternatives, the pendency of re-examinations of the ‘844 Patent and the ‘568 Patent before the PTO, our alleged infringement of the ‘844 Patent and the ‘568 Patent, the validity of the ‘844 Patent and the ‘568 Patent, our expected legal expenses, our exploration of strategic and operational alternatives, the expected recovery of our industry, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock, the cancellation or deferral of customer orders, the risk of a material adverse judgment or increased litigation-related expenses in pending litigation matters, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.
